Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Post by Betteryear2on Oct 26, 2021 5:26pm
256 Views
Post# 34052326

Securityholders Approve Acquisition by Pfizer

Securityholders Approve Acquisition by Pfizer

CAMBRIDGE, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that its securityholders approved a statutory arrangement with PF Argentum ULC (“PF Argentum”) a wholly-owned, indirect subsidiary of Pfizer Inc. (NYSE: PFE) (“Pfizer”) at the special meeting of Trillium securityholders today. Pursuant to the arrangement, PF Argentum will acquire all of the issued and outstanding shares and warrants of Trillium, other than Trillium securities owned by Pfizer and its affiliates.

The special resolution approving the arrangement was approved by: (i) 99.61% of the votes cast by Trillium shareholders voting as a single class present in person or represented by proxy and entitled to vote at the meeting; and (ii) 99.64% of the votes cast by Trillium shareholders and warrant holders, voting as a single class present in person or represented by proxy and entitled to vote at the meeting.

A non-binding resolution approving the compensation that may become payable to certain executive officers of Trillium in connection with the arrangement was also approved by 97.11% of the votes cast by holders of Trillium common shares present in person or represented by proxy at the meeting.

Upon closing of the arrangement, Trillium shareholders other than Pfizer and its affiliates will receive US$18.50 per share in cash subject to any applicable withholdings and other source deductions, and warrant holders will receive, at the holder’s election, (1) a cash payment equal to the amount by which US$18.50 exceeds the exercise price per share of such warrant, subject to applicable withholdings and other source deductions, or (2) a cash payment equal to the Black Scholes value of such warrant (as calculated pursuant to the terms and conditions of the certificate governing such warrant), subject to applicable withholdings and other source deductions.

The arrangement is subject to court and regulatory approvals and clearances, as well as other customary closing conditions. Subject to the satisfaction of such conditions, the transaction is expected to be completed in the fourth quarter of 2021 or the first half of 2022.


https://www.globenewswire.com/news-release/2021/10/26/2321253/33016/en/Trillium-Securityholders-Approve-Acquisition-by-Pfizer.html
<< Previous
Bullboard Posts